公司简介
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...
关联新闻
- Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says
The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats and rising uptake among men accelerate their use, researcher Worldpanel by Numera...
- Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo released full results from a late-stage trial showing Wegovy helped children ages 6 to under 12 with obesity significantly lower their body mass index. Wegovy is already approved to treat obesity...
- Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval
The Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.
- Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
Novo's Wegovy pill helps patients lose about 6% of weight in three months, real-world data show
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of the...
- U.S. regulators are requiring the makers of blockbuster drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss
The FDA is requiring the makers of drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss.
- US FDA orders new eye risk warnings for Ozempic, Zepbound
The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs used for weight loss and diabetes...
- Novo Nordisk stock jumps as Wegovy pill sales beat estimates
Novo Nordisk shares NVO rallied on Wednesday after the Danish drugmaker reported stronger-than-expected third-quarter results, driven by demand for its Wegovy weight-loss pill, and raised its full-yea...